Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S TrialTHROMBOSIS AND HAEMOSTASISIF4.32023-05-124OA
Atorvastatin Versus Placebo In Icu Patients With Covid19: Ninety-day Results Of The INSPIRATION-S TrialARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGYIF7.42023-05-010PRE
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomesEUROPEAN JOURNAL OF INTERNAL MEDICINEIF6.12022-09-016OAAI
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trialTHROMBOSIS RESEARCHIF3.42022-08-0113OAAI
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized TrialTHROMBOSIS AND HAEMOSTASISIF4.32021-06-0659OAAI
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical TrialJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552021-04-27487OA
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center studyTHROMBOSIS RESEARCHIF3.42021-02-0149OAAI
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studiesTHROMBOSIS RESEARCHIF3.42020-12-0151OAAI